SYRE Q3 2021 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

-$13M-961.7% margin

Operating Income

-$20M-1450.5% margin

Net Income

-$20M-1451.5% margin

EPS (Diluted)

$-7.72

QoQ Revenue Growth

-89.8%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$129M

Total Liabilities

$27M

Stockholders' Equity

$102M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	-$13M	$0	—
Operating Income	-$20M	-$18M	-12.0%
Net Income	-$20M	-$18M	-12.6%